Medical Condition News

RSS

FDA clears Aptus’ HeliFX Aortic Securement System

Aptus Endosystems, Inc., a medical device company developing advanced technology for endovascular aneurysm repair (EVAR), announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its thoracic-length HeliFX Aortic Securement System.

From Medtronic 19 Sep 2012

Positive data from Nektar’s NKTR-192 Phase 1a study on acute pain

Nektar Therapeutics announced today that positive data from the first single-ascending dose Phase 1a clinical study of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate, demonstrate that the drug candidate achieved its target pharmacokinetic profile.

19 Sep 2012

Delirium widespread among older people but often goes ignored and untreated

Delirium is widespread among older people but often goes ignored and untreated, according to new research by US and UK researchers including the University of East Anglia (UEA).

19 Sep 2012

Study identifies special gene that regulates bone density and bone strength

A big international study has identified a special gene that regulates bone density and bone strength. The gene can be used as a risk marker for fractures and opens up opportunities for preventive medicine against fractures.

19 Sep 2012

Navidea commences enrollment in [18F]NAV4694 Phase 2 study for Alzheimer's

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that enrollment has commenced at two sites participating in its Phase 2, open-label, safety and efficacy PET imaging study of [18F]NAV4694 for detection of cerebral β-amyloid plaque in subjects diagnosed with probable Alzheimer's disease (AD).

19 Sep 2012

Many women undertreat pelvic floor disorders and suffer in silence

New research issued by the PFD Alliance finds that 90 percent of Americans underestimate or are unsure about the prevalence of pelvic floor disorders (PFDs) which will impact one in three women at some point during their lives. This means many women undertreat PFDs and suffer in silence.

19 Sep 2012

UC San Diego’s bold plan aims to personalize cancer treatment

UC San Diego Moores Cancer Center launched a bold plan today aimed at personalizing cancer treatment. The "My Answer to Cancer" team of oncologists, bioinformaticians, pathologists and geneticists pledges to "sequence" or analyze the DNA of large numbers of patients with cancer in order to match each patient to the best available drug for his or her particular tumor.

19 Sep 2012

BPA exposure not likely to cause obesity, finds study

The American Chemistry Council (ACC) issued the following statement in response to an article in the Journal of the American Medical Association (JAMA) by Leonardo Trasande, M.D., New York University, et al, and scheduled to be discussed at a media briefing on Tuesday, September 18.

19 Sep 2012

Illumina launches new RNA sequencing kits

Illumina today introduced TruSeq Stranded mRNA and Total RNA Sample Preparation Kits for RNA sequencing. The new reagent kits enable researchers to quickly and easily conduct gene expression studies that provide a complete view of the transcriptome, even from low-quality RNA samples, such as formalin-fixed, paraffin-embedded (FFPE) samples.

From Illumina, Inc. 19 Sep 2012

Tranexamic acid: an interview with Prof Ian Roberts

Tranexamic acid is a medicine that reduces blood clot breakdown. In this way it helps in patients with bleeding.

19 Sep 2012

Mental illness campaign launched by Australia’s private hospitals sector

Australia’s private hospitals sector is set to test just how much Australians really know about some of the nation’s most prevalent mental disorders with the launch of its large-scale campaign, ‘What do you know…. about mental illness?’

19 Sep 2012

Pediatric clearance for K2M’s treatment of adolescent idiopathic scoliosis

K2M, Inc., the largest privately held spinal device company in the world focused on developing innovative solutions for the treatment of complex spinal pathologies and minimally invasive procedures, today announced that it has received an additional clearance to treat adolescent idiopathic scoliosis.

18 Sep 2012

Abiraterone acetate confirmed to offer significant survival benefit to advanced prostate cancer patients

Results of a phase 3 trial published in The Lancet Oncology have confirmed that the drug abiraterone acetate (marketed as Zytiga®) offers a significant survival benefit to patients with castration-resistant prostate cancer, which is spreading to other parts of their body (known as metastatic prostate cancer).

18 Sep 2012

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Pfizer Inc. announced today that 14 abstracts for tofacitinib, an investigational oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA), will be presented at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2012 Annual Meeting, which is being held November 9-14 in Washington, D.C.

18 Sep 2012

Cedars-Sinai symposium to discuss latest findings on stem cell treatments for diabetes, eye diseases

Leading scientists and clinicians from across the nation will discuss the latest findings on potential stem cell treatments for diabetes and eye diseases at the second Cedars-Sinai Regenerative Medicine Scientific Symposium.

18 Sep 2012

Thalidomide effective in treating disabling cough among people with idiopathic pulmonary fibrosis

In the first clinical trial to demonstrate an effective treatment for constant, disabling cough among people with idiopathic pulmonary fibrosis (IPF), researchers at the Johns Hopkins University School of Medicine found that taking thalidomide significantly reduced the cough and improved quality of life.

18 Sep 2012

Power of taxane-based chemotherapy drugs may be potentially underestimated

The power of taxane-based chemotherapy drugs are misunderstood and potentially underestimated, according to researchers at Weill Cornell Medical College in the September 15 issue of the journal Cancer Research.

18 Sep 2012

Apixaban offers minor added benefit for adult patients after hip replacement

The clot-inhibiting drug apixaban was approved in May 2011 for the prevention of thrombosis (blood clots) after operations to replace a hip or knee joint.

18 Sep 2012

Study finds major reason why melanoma is largely resistant to chemotherapy

Researchers with UC Irvine's Chao Family Comprehensive Cancer Center have identified a major reason why melanoma is largely resistant to chemotherapy.

18 Sep 2012

No link between low-level electromagnetic field exposure from mobile phones and health risks

There is no scientific evidence that low-level electromagnetic field exposure from mobile phones and other transmitting devices causes adverse health effects, according to a report presented by a Norwegian Expert Committee. In addition, the Committee provides advice to authorities about risk management and regulatory practice.

18 Sep 2012